文献速递炎症性肠病

高压氧治疗因中重度急性发作住院的溃疡性结肠炎患者的2B期随机试验

A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares.
PubMed 文献 · Aliment Pharmacol Ther · 2020-08-03

该2B期随机试验纳入因急性发作住院的溃疡性结肠炎患者(Mayo评分6-12分),先接受3天高压氧(2.4个大气压)联合静脉激素治疗,第3天应答者随机接受5天与3天高压氧。第3天应答率为55%(11/20),5天组疾病活动度下降较3天组更显著(P=0.03),仅3例(15%)需英夫利西单抗或结肠切除术,未观察到治疗相关不良事件。

要点

  • 第3天应答率为55%(11/20),粪便频率、直肠出血和C反应蛋白显著下降(P<0.01)。
  • 5天高压氧较3天更显著降低疾病活动度(P=0.03)。
  • 第3天应答者3个月内再住院或结肠切除率为0%,非应答者为66%(P=0.002)。

核心结论

  • 高压氧似乎对优化住院急性发作溃疡性结肠炎患者对静脉激素的应答有效,3个月再住院或结肠切除率低。
  • 5天高压氧可获得最佳临床应答。
  • 需要更大规模的3期试验来确认疗效并获得标签批准。

研究设计与样本

  • 2B期随机试验,纳入因急性发作住院的溃疡性结肠炎患者(Mayo评分6-12分)。
  • 所有患者先接受3天高压氧(2.4个大气压,90分钟含两次空气休息)联合静脉激素治疗。
  • 第3天应答者(部分Mayo评分降低≥2分且直肠出血评分降低≥1分)随机接受总共5天与3天高压氧。
  • 共治疗20例患者,75%既往生物制剂治疗失败。

主要发现

  • 第3天应答率为55%(n=11/20),粪便频率、直肠出血和C反应蛋白显著下降(P<0.01)。
  • 5天高压氧较3天高压氧观察到更显著的疾病活动度下降(P=0.03)。
  • 仅3例患者(15%)需要英夫利西单抗或结肠切除术,尽管二线治疗的预测概率为80%。
  • 第3天高压氧应答者3个月内再住院或结肠切除率低于非应答者(0% vs 66%,P=0.002)。
  • 未观察到治疗相关不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大规模的3期试验来确认疗效并获得标签批准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hyperbaric oxygen has been reported to improve disease activity in hospitalised ulcerative colitis (UC) patients. AIM: To evaluate dosing strategies with hyperbaric oxygen for hospitalised UC patients. METHODS: We enrolled UC patients hospitalised for acute flares (Mayo score 6-12). Initially, all patients received 3 days of hyperbaric oxygen at 2.4 atmospheres (90 minutes with two air breaks) in addition to intravenous steroids. Day 3 responders (reduction of partial Mayo score ≥ 2 points and rectal bleeding score ≥ 1 point) were randomised to receive a total of 5 days vs 3 days of hyperbaric oxygen. RESULTS: We treated 20 patients with hyperbaric oxygen (75% prior biologic failure). Day 3 response was achieved in 55% (n = 11/20), with significant reductions in stool frequency, rectal bleeding and CRP (P < 0.01). A more significant reduction in disease activity was observed with 5 days vs 3 days of hyperbaric oxygen (P = 0.03). Infliximab or colectomy was required in only three patients (15%) despite a predicted probability of 80% for second-line therapy. Day 3 hyperbaric oxygen responders were less likely to require re-hospitalisation or colectomy by 3 months vs non-responders (0% vs 66%, P = 0.002). No treatment-related adverse events were observed. CONCLUSION: Hyperbaric oxygen appears to be effective for optimising response to intravenous steroids in UC patients hospitalised for acute flares, with low rates of re-hospitalisation or colectomy at 3 months. An optimal clinical response is achieved with 5 days of hyperbaric oxygen. Larger phase 3 trials are needed to confirm efficacy and obtain labelled approval.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Raffals LE, Hudesman D, et al. A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. Aliment Pharmacol Ther. 2020. PMID: 32745306. doi:10.1111/apt.15984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。